{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:31:51Z","timestamp":1793370711437,"version":"4.5.0"},"reference-count":77,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,12,1]]},"DOI":"10.1001\/jamaoncol.2019.3541","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T11:04:15Z","timestamp":1571310255000},"page":"1739","source":"Crossref","is-referenced-by-count":110,"title":["Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers"],"prefix":"10.1001","volume":"5","author":[{"given":"Nico","family":"Gagelmann","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bacigalupo","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli Institute of Scientific Research and Treatment, Universita' Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Hoelzer","sequence":"additional","affiliation":[{"name":"Goethe University Hospital, Department of Medicine II, Hematology\/Oncology, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Halter","sequence":"additional","affiliation":[{"name":"Division of Hematology, Basel University Hospital, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bonifazi","sequence":"additional","affiliation":[{"name":"Department of Hematology, L and A Ser\u00e0gnoli, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Meijer","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center, Vrije Universiteit, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"It\u00e4l\u00e4-Remes","sequence":"additional","affiliation":[{"name":"Turku University Hospital, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark\u00e9ta","family":"Markov\u00e1","sequence":"additional","affiliation":[{"name":"Institute for Hematology and Blood Transfusion, Hospital Na Bulovce, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Solano","sequence":"additional","affiliation":[{"name":"Hospital Clinico Universitario-INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"coi190071r1","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/bmt.2017.34","article-title":"Use of haploidentical stem cell transplantation continues to increase.","volume":"52","author":"Passweg","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"coi190071r2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbmt.2007.10.010","article-title":"Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.","volume":"14","author":"Saito","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"coi190071r3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJM198509263131301","article-title":"Marrow transplantation from related donors other than HLA-identical siblings.","volume":"313","author":"Beatty","year":"1985","journal-title":"N Engl J Med"},{"issue":"5","key":"coi190071r4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1200\/JCO.1997.15.5.1767","article-title":"Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.","volume":"15","author":"Szydlo","year":"1997","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi190071r5","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/S2352-3026(15)00028-9","article-title":"One million haemopoietic stem-cell transplants.","volume":"2","author":"Gratwohl","year":"2015","journal-title":"Lancet Haematol"},{"issue":"26","key":"coi190071r6","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1200\/JCO.2017.73.7775","article-title":"Haploidentical hematopoietic cell transplantation using post-transplantation cyclophosphamide: does graft source matter?","volume":"35","author":"Devine","year":"2017","journal-title":"J Clin Oncol"},{"key":"coi190071r7","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-019-0465-9","article-title":"The EBMT activity survey report 2017","author":"Passweg","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"coi190071r8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide.","volume":"8","author":"O\u2019Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"coi190071r9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"coi190071r10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41409-018-0239-9","article-title":"Haploidentical versus matched donor stem cell transplantation for patients with hematological malignancies.","volume":"54","author":"Yang","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"38","key":"coi190071r11","doi-asserted-by":"publisher","first-page":"63574","DOI":"10.18632\/oncotarget.v8i38","article-title":"Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation.","volume":"8","author":"Gu","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"coi190071r12","doi-asserted-by":"publisher","first-page":"e0191955","DOI":"10.1371\/journal.pone.0191955","article-title":"Comparison of outcomes in hematological malignancies treated with haploidentical or HLA-identical sibling hematopoietic stem cell transplantation following myeloablative conditioning.","volume":"13","author":"Chen","year":"2018","journal-title":"PLoS One"},{"key":"coi190071r13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.critrevonc.2018.05.017","article-title":"Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide.","volume":"133","author":"Yu","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"coi190071r15","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"15","key":"coi190071r16","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis of Observational Studies in Epidemiology (MOOSE) group.","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"issue":"23","key":"coi190071r17","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"8","key":"coi190071r18","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index.","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"8","key":"coi190071r19","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"issue":"4","key":"coi190071r20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","article-title":"Definition of GvHD-free, relapse-free survival for registry-based studies.","volume":"51","author":"Ruggeri","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"coi190071r21","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7650","key":"coi190071r22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"2","key":"coi190071r24","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1002\/acg2.v1.2","article-title":"The science of evidence synthesis in hematopoietic stem-cell transplantation.","volume":"1","author":"Gagelmann","year":"2018","journal-title":"Adv Cell Gene Ther"},{"issue":"3","key":"coi190071r25","first-page":"40","article-title":"meta: An R package for meta-analysis.","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R News"},{"issue":"3","key":"coi190071r26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package.","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"issue":"7","key":"coi190071r28","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.bbmt.2015.03.003","article-title":"Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors.","volume":"21","author":"Solomon","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"coi190071r29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bbmt.2015.09.002","article-title":"Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors.","volume":"22","author":"Bashey","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"coi190071r30","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.bbmt.2016.05.010","article-title":"Comparison of outcomes after peripheral blood haploidentical versus matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.","volume":"22","author":"Rashidi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"coi190071r31","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.bbmt.2017.08.030","article-title":"Donor type and disease risk predict the success of allogeneic hematopoietic cell transplantation.","volume":"23","author":"Solh","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"coi190071r32","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"10","key":"coi190071r33","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-cell\u2013replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.","volume":"31","author":"Bashey","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi190071r34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bbmt.2015.08.029","article-title":"Haploidentical T cell-replete transplantation with post-transplantation cyclophosphamide for patients in or above the sixth decade of age compared with allogeneic hematopoietic stem cell transplantation from an human leukocyte antigen-matched related or unrelated donor.","volume":"22","author":"Blaise","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"coi190071r35","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"issue":"4","key":"coi190071r37","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.bbmt.2018.12.142","article-title":"Higher incidence of hemorrhagic cystitis following haploidentical related donor transplantation compared with matched related donor transplantation.","volume":"25","author":"Copelan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"30","key":"coi190071r38","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","article-title":"Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma.","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi190071r39","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.bbmt.2017.01.068","article-title":"T cell-replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia.","volume":"23","author":"How","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"coi190071r40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3324\/haematol.2016.144139","article-title":"Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.","volume":"102","author":"McCurdy","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"coi190071r41","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.bbmt.2018.02.002","article-title":"HLA-matched sibling versus unrelated versus haploidentical related donor allogeneic hematopoietic stem cell transplantation for patients aged over 60 years with acute myeloid leukemia.","volume":"24","author":"Devillier","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"coi190071r42","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3324\/haematol.2017.187450","article-title":"Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia.","volume":"104","author":"Brissot","year":"2019","journal-title":"Haematologica"},{"issue":"26","key":"coi190071r43","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors.","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi190071r44","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/ejh.2018.100.issue-5","article-title":"Risk-adapted GVHD prophylaxis with post-transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations.","volume":"100","author":"Moiseev","year":"2018","journal-title":"Eur J Haematol"},{"issue":"7","key":"coi190071r45","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/s41409-018-0387-y","article-title":"Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies","volume":"54","author":"Pagliardini","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"coi190071r46","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1182\/bloodadvances.2018018291","article-title":"Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?","volume":"2","author":"Robinson","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"coi190071r47","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"coi190071r48","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.bbmt.2018.08.026","article-title":"HLA-mismatched donors in patients with myelodysplastic syndrome.","volume":"25","author":"Robin","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"coi190071r49","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.bbmt.2014.08.013","article-title":"Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10\/10 human leukocyte antigen-matched unrelated and related donors.","volume":"20","author":"Di Stasi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"coi190071r50","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1182\/bloodadvances.2019000050","article-title":"Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.","volume":"3","author":"Rashidi","year":"2019","journal-title":"Blood Adv"},{"key":"coi190071r51","first-page":"S1083-8791(19)30336-2","article-title":"Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"coi190071r53","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.bbmt.2019.02.002","article-title":"Impact of donor type and melphalan dose on allogeneic transplantation outcomes for patients with lymphoma.","volume":"25","author":"Saini","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"coi190071r54","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-019-0459-7","article-title":"Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed\/refractory acute myeloid leukemia","author":"Battipaglia","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"coi190071r55","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1182\/blood-2018-99-114770","article-title":"Comparable survival outcomes of haploidentical stem cell transplantation and unrelated bone marrow transplantation.","volume":"132","author":"Sugita","year":"2018","journal-title":"Blood"},{"issue":"4","key":"coi190071r56","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41409-017-0018-z","article-title":"Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin\u2019s lymphoma undergoing allogeneic haematopoietic cell transplantation.","volume":"53","author":"Gauthier","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"coi190071r57","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.bbmt.2014.05.029","article-title":"Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.","volume":"20","author":"Raiola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"coi190071r58","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.3324\/haematol.2017.176107","article-title":"Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia.","volume":"102","author":"Lee","year":"2017","journal-title":"Haematologica"},{"key":"coi190071r59","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-018-0332-0","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation","author":"Ciurea","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"coi190071r60","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation.","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"coi190071r61","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1182\/blood-2016-09-737825","article-title":"Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.","volume":"129","author":"Kanakry","year":"2017","journal-title":"Blood"},{"issue":"2","key":"coi190071r62","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.bbmt.2017.10.023","article-title":"Grade II acute graft-versus-host disease and higher nucleated cell graft dose improve progression-free survival after HLA-haploidentical transplant with post-transplant cyclophosphamide.","volume":"24","author":"McCurdy","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"coi190071r63","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.bbmt.2013.07.013","article-title":"Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.","volume":"19","author":"Kanakry","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"coi190071r64","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/tid.2015.17.issue-2","article-title":"Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis.","volume":"17","author":"Crocchiolo","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"coi190071r65","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00277-015-2423-y","article-title":"Virus infection in HLA-haploidentical hematopoietic stem cell transplantation.","volume":"94","author":"Tischer","year":"2015","journal-title":"Ann Hematol"},{"key":"coi190071r66","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression.","volume":"130","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"issue":"211","key":"coi190071r67","doi-asserted-by":"publisher","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide.","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"issue":"11","key":"coi190071r68","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","article-title":"Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.","volume":"127","author":"Mielcarek","year":"2016","journal-title":"Blood"},{"issue":"31","key":"coi190071r69","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.","volume":"32","author":"Kanakry","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi190071r70","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.bbmt.2018.12.767","article-title":"Development of grade II acute graft-versus-host disease is associated with improved survival after myeloablative HLA-matched bone marrow transplantation using single-agent post-transplant cyclophosphamide.","volume":"25","author":"McCurdy","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"coi190071r71","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/bloodadvances.2016002196","article-title":"Related haploidentical donors are a better choice than matched unrelated donors: point.","volume":"1","author":"Fuchs","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"coi190071r72","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/blood-2010-01-264077","article-title":"The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome\u2013negative acute lymphoblastic leukemia in first and second complete remission.","volume":"116","author":"Marks","year":"2010","journal-title":"Blood"},{"issue":"11","key":"coi190071r73","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes.","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"19","key":"coi190071r74","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome.","volume":"35","author":"Kr\u00f6ger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"20","key":"coi190071r75","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood"},{"issue":"5","key":"coi190071r76","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.bbmt.2013.01.024","article-title":"Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"coi190071r77","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","article-title":"Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.","volume":"14","author":"Burroughs","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"coi190071r36","author":"Al Malki","year":"2019"},{"key":"coi190071r52","author":"Gopcsa","year":"2019"},{"key":"coi190071r14","unstructured":"HigginsJPT, GreenS, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. http:\/\/handbook-5-1.cochrane.org\/. Updated March 2011. Accessed March 9, 2019."},{"key":"coi190071r23","unstructured":"GRADEpro. McMaster University, 2015, Evidence Prime, Inc. https:\/\/gradepro.org\/. Published 2015. Accessed March 20, 2019."},{"key":"coi190071r27","unstructured":"R Core Team. The R project for Statistical Computing. https:\/\/www.R-project.org\/. Accessed March 20, 2019."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2752787\/jamaoncology_gagelmann_2019_oi_190071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T22:19:37Z","timestamp":1611526777000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2752787"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":77,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.3541","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}